Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 476

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 476
---
ucco.Please see “ Management of the Company Prior to the Business Combination — Executive Officers.” Sandra Sánchez -Oldenhage .Upon the Closing of the Business Combination, Ms. Oldenhage is expected to serve as non -executivedirector of the Company. Sandra Sánchez -Oldenhageis a seasoned executive with 37 years of leadership in the life sciences sector, specializing in strategic growth and transformation across Latin America. She has held senior roles at global pharmaceutical leaders including Pfizer, Merck, and Novartis, and led the successful market entry and expansion of Amgen and Biogen in Mexico. As founder and CEO of PharmAdvice, she advises companies on commercial strategy, regulatory affairs, and market access. Recognized among Mexico’s top businesswomen by CNN Expansión and Forbes, Sandra has served on numerous boards including PROCAPS Group (NASDAQ: PROC), Centro Médico ABC, and CANIFARMA. She holds an MBA from ITESM, and executive education credentials from Harvard, Cambridge, and Washington University in St. Louis. Directors and Senior Management Compensation Following the Closing of the Business Combination, we expect our executive compensation program to reflect our compensation policies and philosophies, as they may be modified and updated from time to time. We expect that decisions with respect to the compensation of our executive officers and senior management team, including our named 247 executive officers, will be made prior to or following the Closing of the Business Combination by the Compensation Committee of our Board and, to the extent necessary, ratified by our board of directors and subject to shareholders’ approval. Our executive compensation programs for 2023 are further described above under “ Management of the Company — Company’s Executive Compensation” and “Management of the Company — Director Compensation.” Foreign Private Issuer Exemption As a “foreign private issuer,” as defined by the SEC, we are permitted to follow, and expect to follow, home country corporate governance practices, instead of certain corporate governance practices required by Nasdaq for U.S. domestic issuers other than with respect to certain voting and committee requirements. A foreign private issuer must disclose in its Annual Reports filed with the SEC each Nasdaq requirement with which it does not comply followed by a description of its applicable home country practice. As an exempted company incorporated in the Cayman Islands and expected to be listed on the Nasdaq, we intend to follow our home country practice with respect to the composition of our board of directors and nominations committee and executive sessions. Unlike the requirements of the Nasdaq, the corporate governance practice and